

## General

### Title

Diagnosis and treatment of ischemic stroke: percentage of patients who receive appropriate intervention for hypoglycemia and hyperglycemia.

### Source(s)

Anderson D, Larson D, Bluhm J, Charipar R, Fiscus L, Hanson M, Larson J, Rabinstein A, Wallace G, Zinkel A. Diagnosis and initial treatment of ischemic stroke. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2012 Jul. 122 p. [238 references]

## Measure Domain

### Primary Measure Domain

Clinical Quality Measures: Process

### Secondary Measure Domain

Does not apply to this measure

## Brief Abstract

### Description

This measure is used to assess the percentage of patients age 18 years and older initially presenting with acute symptoms of ischemic stroke who receive appropriate intervention for hypoglycemia and hyperglycemia.

### Rationale

The priority aim addressed by this measure is to increase the percentage of stroke patients age 18 years and over who receive appropriate medical management within the initial 24 to 48 hours of diagnosis for prevention of complications such as:

- Dehydration
- Aspiration
- Hypoglycemia and hyperglycemia

Deep vein thrombosis  
Immobility  
Falling  
Nutritional status decline  
Hyperthermia

Stroke is the fourth leading cause of death, recently dropping from third after decades long efforts to reduce incidence by treatment of risk factors. It remains the leading cause of disability among adults. Costs of hospitalizations, other cares and lost wages are simply enormous.

Detecting and treating hypoglycemia is a leading priority in managing patients presenting with stroke syndrome. Indeed, the stroke may be cured by giving glucose, since hypoglycemia is a famous stroke mimicker by producing asymmetric neurologic deficits. An evidence-based threshold for giving a bolus of glucose is not established.

Hyperglycemic control, although deemed important to treat, based on expert opinion, has not been adequately studied in the presence of the acute stroke phase.

Most observational studies document either increased mortality or decreased functional outcome, or both, with higher glucose levels. Some have speculated that early hyperglycemia in the setting of acute stroke is simply a marker of physiologic stress and an epiphenomenon in those who have suffered severe stroke. Others have documented that it is an independent predictor of poor outcome and propose that it has a causative role. Despite the extensive body of literature describing this relationship, a definitive clinical trial of managing hyperglycemia in ischemic stroke patients to improve outcome is still lacking. It remains unclear whether early hyperglycemia in the setting of acute stroke is a marker of physiologic stress or an independent predictor of poor outcome. Usual management of hyperglycemia (glucose levels greater than 180 mg/dL) with gentle dosing of subcutaneous insulin, avoiding hypoglycemia, in a timely manner during acute ischemia would seem prudent until ongoing clinical trials address the appropriateness of more aggressive treatment measures.

## Evidence for Rationale

Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EFM, American Heart Association, American Stroke Association Stroke Council, Clinical Cardiology Council. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology [trunc]. Stroke. 2007 May;38(5):1655-711. [738 references] [PubMed](#)

Anderson D, Larson D, Bluhm J, Charipar R, Fiscus L, Hanson M, Larson J, Rabinstein A, Wallace G, Zinkel A. Diagnosis and initial treatment of ischemic stroke. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2012 Jul. 122 p. [238 references]

Baird TA, Parsons MW, Phan T, Butcher KS, Desmond PM, Tress BM, Colman PG, Chambers BR, Davis SM. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003 Sep;34(9):2208-14. [PubMed](#)

Bruno A, Biller J, Adams HP Jr, Clarke WR, Woolson RF, Williams LS, Hansen MD. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999 Jan 15;52(2):280-4. [PubMed](#)

Jorgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke. 1994 Oct;25(10):1977-84. [PubMed](#)

Kiers L, Davis SM, Larkins R, Hopper J, Tress B, Rossiter SC, Carlin J, Ratnaike S. Stroke topography

and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry. 1992 Apr;55(4):263-70. [PubMed](#)

Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke. 2004 Feb;35(2):363-4. [PubMed](#)

Woo J, Lam CW, Kay R, Wong AH, Teoh R, Nicholls MG. The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol. 1990 Nov;47(11):1174-7. [PubMed](#)

## Primary Health Components

Ischemic stroke; hypoglycemia; hyperglycemia

## Denominator Description

Number of patients presenting with acute symptoms of ischemic stroke (see the related "Denominator Inclusions/Exclusions" field)

## Numerator Description

Number of patients who have appropriate intervention for hypoglycemia and hyperglycemia

## Evidence Supporting the Measure

### Type of Evidence Supporting the Criterion of Quality for the Measure

A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

### Additional Information Supporting Need for the Measure

Unspecified

### Extent of Measure Testing

Unspecified

## State of Use of the Measure

### State of Use

Current routine use

### Current Use

not defined yet

# Application of the Measure in its Current Use

## Measurement Setting

Emergency Department

Hospital Inpatient

## Professionals Involved in Delivery of Health Services

not defined yet

## Least Aggregated Level of Services Delivery Addressed

Single Health Care Delivery or Public Health Organizations

## Statement of Acceptable Minimum Sample Size

Unspecified

## Target Population Age

Age greater than or equal to 18 years

## Target Population Gender

Either male or female

# National Strategy for Quality Improvement in Health Care

## National Quality Strategy Aim

Better Care

## National Quality Strategy Priority

Prevention and Treatment of Leading Causes of Mortality

# Institute of Medicine (IOM) National Health Care Quality Report Categories

## IOM Care Need

Getting Better

# IOM Domain

Effectiveness

## Data Collection for the Measure

### Case Finding Period

The time frame pertaining to data collection is monthly.

### Denominator Sampling Frame

Patients associated with provider

### Denominator (Index) Event or Characteristic

Clinical Condition

Encounter

Patient/Individual (Consumer) Characteristic

### Denominator Time Window

not defined yet

### Denominator Inclusions/Exclusions

Inclusions

Number of patients presenting with acute symptoms of ischemic stroke

Population Definition: Patients age 18 years and older.

Exclusions

Unspecified

### Exclusions/Exceptions

not defined yet

### Numerator Inclusions/Exclusions

Inclusions

Number of patients who have appropriate intervention for hypoglycemia and hyperglycemia

Exclusions

Unspecified

### Numerator Search Strategy

Fixed time period or point in time

## Data Source

Paper medical record

## Type of Health State

Does not apply to this measure

## Instruments Used and/or Associated with the Measure

Unspecified

## Computation of the Measure

### Measure Specifies Disaggregation

Does not apply to this measure

## Scoring

Rate/Proportion

## Interpretation of Score

Desired value is a higher score

## Allowance for Patient or Population Factors

not defined yet

## Standard of Comparison

not defined yet

## Identifying Information

### Original Title

Percentage of patients who receive appropriate intervention for hypoglycemia and hyperglycemia.

### Measure Collection Name

Diagnosis and Treatment of Ischemic Stroke

## Submitter

## Developer

Institute for Clinical Systems Improvement - Nonprofit Organization

## Funding Source(s)

The Institute for Clinical Systems Improvement's (ICSI's) work is funded by the annual dues of the member medical groups and five sponsoring health plans in Minnesota and Wisconsin.

## Composition of the Group that Developed the Measure

*Work Group Members:* David Anderson, MD (*Work Group Co-Leader*) (University of Minnesota Physicians and Hennepin County Medical Center) (Neurology); David Larson, MD, FACEP (*Work Group Co-Leader*) (Ridgeview Medical Center) (Emergency Medicine); Gail Wallace, NP (Essentia Health) (Nursing); Lynne Fiscus, MD, MPH (Fairview Health Services) (Internal Medicine and Pediatrics); Andrew Zinkel, MD (HealthPartners Medical Group and Regions Hospital) (Emergency Medicine); Ron Charipar, MD (Marshfield Clinic) (Internal Medicine and Pediatrics); Alejandro Rabinstein, MD (Mayo Clinic) (Neurology); Jeff Larson, PharmD (Park Nicollet Health Services) (Pharmacy); Myounghee Hanson, BA (Institute for Clinical Systems Improvement) (Clinical Systems Improvement Facilitator); Jim Bluhm, MPH (Institute for Clinical Systems Improvement) (Team Director)

## Financial Disclosures/Other Potential Conflicts of Interest

David Anderson, MD (Work Group Leader)

Professor, Neurology Department, Neurology, University of Minnesota Physicians and Hennepin County Medical Center

National, Regional, Local Committee Affiliations: NNINDS NHLBI as an event adjudicator for two clinical trials: SAMMPRIS (Stenting Versus Aggressive Medical Management for Preventing Recurrent Stroke), and AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes)

Guideline-Related Activities: None

Research Grants: None

Financial/Non-Financial Conflicts of Interest: MN Acute Stroke Systems Council, MDH and member of MN Time Critical Care Committee, MDH

Ron Charipar, MD (Work Group Member)

Professor, Internal Medicine, Marshfield Clinic

National, Regional, Local Committee Affiliations: None

Guideline-Related Activities: None

Research Grants: None

Financial/Non-Financial Conflicts of Interest: None

Lynne Fiscus, MD, MPH (Work Group Member)

Internal Medicine and Pediatrics, Department, Fairview Health Services

National, Regional, Local Committee Affiliations: None

Guideline-Related Activities: None

Research Grants: None

Financial/Non-Financial Conflicts of Interest: None

David Larson, MD, FACEP (Work Group Member)

Medical Director, Ridgeview Emergency Department, Ridgeview Medical Center

National, Regional, Local Committee Affiliations: None

Guideline-Related Activities: None

Research Grants: None

Financial/Non-Financial Conflicts of Interest: Clinical Advisory Panel Leader, TogetherMD, LLC, MN Acute Stroke Systems Council, MDH and member of MN Time Critical Care Committee, MDH

Jeff Larson, PharmD (Work Group Member)

Staff Pharmacist, Pharmacy, Park Nicollet Health Services

National, Regional, Local Committee Affiliations: None

Guideline-Related Activities: None

Research Grants: None

Financial/Non-Financial Conflicts of Interest: None

Alejandro Rabinstein, MD (Work Group Member)

Professor, Neurology, Mayo Clinic

National, Regional, Local Committee Affiliations: None

Guideline-Related Activities: None

Research Grants: Cardionet, MCOT use for an investigator-initiated project

Financial/Non-Financial Conflicts of Interest: Member of the Data Safety Monitoring Board for the PREVAIL study by ARTITECH (now Boston Scientific)

Gail Wallace, NP (Work Group Member)

Neurology Nurse Practitioner, Nursing, Essentia Health East Region

National, Regional, Local Committee Affiliations: None

Guideline-Related Activities: None

Research Grants: None

Financial/Non-Financial Conflicts of Interest: None

Andrew Zinkel, MD (Work Group Member)

Section Head and Medical Director of Quality, Department of Emergency Medicine, HealthPartners Medical Group and Regions Hospital

National, Regional, Local Committee Affiliations: None

Guideline-Related Activities: None

Research Grants: None

Financial/Non-Financial Conflicts of Interest: Clinical Advisory Panel Leader, TogetherMD, LLC

## Adaptation

This measure was not adapted from another source.

## Date of Most Current Version in NQMC

2012 Jul

## Measure Maintenance

Scientific documents are revised every 12 to 24 months as indicated by changes in clinical practice and literature.

## Date of Next Anticipated Revision

The next scheduled revision will occur within 24 months.



## Measure Status

This is the current release of the measure.

The measure developer reaffirmed the currency of this measure in January 2016.

## Measure Availability

Source available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#)

.

For more information, contact ICSI at 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; Phone: 952-814-7060; Fax: 952-858-9675; Web site: [www.icsi.org](http://www.icsi.org) ; E-mail: [icsi.info@icsi.org](mailto:icsi.info@icsi.org).

## NQMC Status

This NQMC summary was completed by ECRI Institute on November 14, 2012.

The information was reaffirmed by the measure developer on January 13, 2016.

## Copyright Statement

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

## Production

### Source(s)

Anderson D, Larson D, Bluhm J, Charipar R, Fiscus L, Hanson M, Larson J, Rabinstein A, Wallace G, Zinkel A. Diagnosis and initial treatment of ischemic stroke. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2012 Jul. 122 p. [238 references]

## Disclaimer

### NQMC Disclaimer

The National Quality Measures Clearinghouse<sup>®</sup> (NQMC) does not develop, produce, approve, or endorse

the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the [NQMC Inclusion Criteria](#).

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.